{"id":47779,"date":"2022-08-29T23:02:09","date_gmt":"2022-08-29T21:02:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/"},"modified":"2022-08-29T23:02:09","modified_gmt":"2022-08-29T21:02:09","slug":"anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/","title":{"rendered":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix"},"content":{"rendered":"
\n

MUMBAI, India–(BUSINESS WIRE)–#asia<\/a>–Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio \/ Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States.\n<\/p>\n

\nAnuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targets and pathways with the ultimate goal of providing better health for all.\n<\/p>\n

\nAnuva\u2019s partnership with Helix will allow the company to leverage Helix\u2019s deep expertise in sequencing technology and translational research. Helix\u2019s proprietary Exome+\u00ae assay will provide Anuva higher coverage on clinically relevant genes and a whole genome backbone enabling tens of millions of imputed variants as well as the full mitochondrial genome. Combined with Anuva\u2019s proprietary Genomic Bio \/ Data Bank, which incorporates genomic data and deeply phenotyped participants, along with a biorepository from diverse Asian subpopulations, Anuva will be able to create the largest multi-population dataset from Asia.\n<\/p>\n

\nAbhishek Kumar, Director at Anuva said \u201cWe are excited to partner with Helix as their expertise in genomics sequencing for large-scale populations, which together with our recent closure of series A funding will allow us to accelerate our plans to create the most diverse Genomic Bio \/ Data Bank much quicker than ever before.\u201d\n<\/p>\n

\n\u201cAnuva is doing great work to close the critical data diversity gap in genomics for drug discovery,\u201d said Daniel Lee, Senior Vice President of Life Sciences and Growth at Helix. \u201cWe\u2019re thrilled to be able to provide Anuva access to our whole exome assay as they enter their next stage of growth.\u201d\n<\/p>\n

\nRapid development in technology to study genomics is disrupting the entire healthcare sector as focus turns to providing personalized healthcare with a high degree of effectiveness compared to the current methods. As technology evolves, business models and industry partnerships will need to adapt to bring the full potential of genomics to the global population. Anuva\u2019s partnership with Helix marks a significant step in that direction. Anuva\u2019s creation of this previously unavailable dataset will empower drug discovery researchers to explore human health to a greater extent than ever done before. This new understanding will enable the discovery of novel biological targets and pathways that inform the development of treatments and also identify who would benefit most from them.\n<\/p>\n

\nAbout Anuva\n<\/p>\n

\nAnuva is a translational research company that is creating the most diverse Genomic Bio\/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. In addition, our cohorts and biorepository allows for follow-on clinical and translational studies, which greatly empower drug development opportunities.\n<\/p>\n

\nAbout Helix\n<\/p>\n

\nHelix is the leading population genomics and viral surveillance company. Helix enables health systems, public health organizations and life sciences companies to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAnuva: communications@anuva.bio<\/a>
Helix: press@helix.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MUMBAI, India–(BUSINESS WIRE)–#asia–Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio \/ Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47779","6":"format-standard","7":"category-industry"},"yoast_head":"\nAnuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MUMBAI, India–(BUSINESS WIRE)–#asia–Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio \/ Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-29T21:02:09+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix\",\"datePublished\":\"2022-08-29T21:02:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/\"},\"wordCount\":530,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/\",\"name\":\"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-29T21:02:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/","og_locale":"en_US","og_type":"article","og_title":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend","og_description":"MUMBAI, India–(BUSINESS WIRE)–#asia–Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio \/ Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-29T21:02:09+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix","datePublished":"2022-08-29T21:02:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/"},"wordCount":530,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/","url":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/","name":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-29T21:02:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/anuva-announces-series-a-closure-and-enters-into-a-strategic-partnership-with-helix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47779"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47779\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}